Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: In-vehicle Device Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promoting Intrafamily Accountability for Reducing Cellphone Use While Driving in Adults and Their Teen Children

NCT02923271
View directory record Official record
Conditions
Teen Drivers, Motor Vehicle Accidents
Interventions
CellControl
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
16 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 3, 2026, 6:41 AM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

NCT07144852
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Health Literacy and Obesogenic Behaviors

NCT04252677
View directory record Official record
Conditions
Obesity, Adolescent, Health Behavior, Health Knowledge, Attitudes, Practice, Diet, Healthy, Exercise, Health Literacy
Interventions
Obesity Prevention, Health Literacy
Behavioral
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
13 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Biomechanics of Wheelchair Transfers

NCT00645567
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Unassisted Manual Transfer, Standard Transfer Board, Glide n' Go, Easy Reach lift, Ryno lift
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 3, 2026, 6:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Early Phase 1 Interventional

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

NCT06366451
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

NCT03442751
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Test Article A, Test Article B, Placebo, KXL medical device system
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 3, 2026, 6:41 AM EDT
Terminated Early Phase 1 Interventional

Intratumoral Microdosing of Motolimod in HNSCC

NCT04272333
View directory record Official record
Conditions
HNSCC
Interventions
Motolimod, Nivolumab, Motolimod + Nivolumab
Drug · Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Early Phase 1 Interventional

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

NCT06062602
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
TAK-676, Carboplatin, 5-FU, Paclitaxel, TAK-676 + Carboplatin, Carboplatin + Paclitaxel, Carboplatin + 5-FU, TAK-676 + Carboplatin + 5-FU, TAK-676 + Carboplatin + Paclitaxel
Drug · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Shreveport, Louisiana • The Bronx, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Way to Safety Cellphone Blocking

NCT02416713
View directory record Official record
Conditions
Teen Drivers, Motor Vehicle Accident
Interventions
Cellcontrol DriveID, Education Only
Device · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
16 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Sep 3, 2026, 6:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation

NCT06149780
View directory record Official record
Conditions
Healthy
Interventions
Patients treated with laser
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 3, 2026, 6:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alcohol Impairment Detection in Healthy Adult Users With the Gaize Device

NCT07126938
View directory record Official record
Conditions
Alcohol Impairment, Nystagmus, Virtual Reality, Lack of Smooth Pursuit, Impairment, Alcohol Intoxication, Intoxication
Interventions
Alcoholic beverage
Drug
Lead sponsor
Gaize
Industry
Eligibility
21 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Early Phase 1 Interventional

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

NCT06413095
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions
Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Intervention to Improve Driving Practices Among High-Risk Teen Drivers

NCT04317664
View directory record Official record
Conditions
Drive, Recidivism, Communication, Feedback, Psychological
Interventions
In-vehicle device, Parent Communication
Combination Product · Behavioral
Lead sponsor
Ginger Yang
Other
Eligibility
16 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Early Phase 1 Interventional

Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)

NCT02710162
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Micro Mouth Pressure Meter, Iowa Oral Performance Instrument, Electrical Impedance Myography, Capsaicin, Videofluoroscopic Swallowing Study, Pulmonary Function Testing, Swallowing Related Quality of Life Questionnaire, Functional Oral Intake Scale, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Eating Assessment Tool-10, Communicative Effectiveness Survey, The Center for Neurologic Studies Bulbar Function Scale
Device · Drug · Procedure + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 3, 2026, 6:41 AM EDT
Active, not recruiting Early Phase 1 Interventional

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NCT04541108
View directory record Official record
Conditions
Solid Tumor
Interventions
Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
9
States / cities
Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Early Phase 1 Interventional

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

NCT04065555
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
TAK-981, Cetuximab, Avelumab, TAK-981 + Cetuximab, TAK-981 + Avelumab
Drug · Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Controlled Trial to Improve Teen Driving

NCT01624597
View directory record Official record
Conditions
Motor Vehicle Driving
Interventions
In-vehicle video feedback, Parent communication
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
14 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
2
States / cities
Des Moines, Iowa • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Commute Traffic on Vascular Function

NCT05454930
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Filtered Air
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Not applicable Interventional

Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris

NCT02217228
View directory record Official record
Conditions
Inflammatory Acne Vulgaris
Interventions
Sebacia microparticles and laser, Vehicle suspension and laser, Sebacia microparticles without laser
Device
Lead sponsor
Sebacia, Inc.
Industry
Eligibility
15 Years to 35 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Scottsdale, Arizona • Sacramento, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 1Phase 2 Interventional

The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence

NCT02590393
View directory record Official record
Conditions
Nicotine Dependence
Interventions
E-cigarettes
Combination Product
Lead sponsor
Duke University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 3, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

NCT02493257
View directory record Official record
Conditions
Nonallergic Irritant Rhinitis
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 3, 2026, 6:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improving Diagnostic Standards in Dysphagia

NCT04773184
View directory record Official record
Conditions
Dysphagia
Interventions
Fiberoptic Endoscopic Evaluation of Swallowing, Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, Iowa Oral Performance Instrument, Capsaicin Challenge, Pulmonary Function Testing, Voicing Tasks
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 3, 2026, 6:41 AM EDT
Not listed Phase 1Phase 2 Interventional

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

NCT04071600
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions
Neuropeptide Y, Placebo
Drug · Other
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 3, 2026, 6:41 AM EDT